Filing summary
Entity mismatch: The request identifies Newegg Commerce, Inc., but the supplied Form 10-Q is for Dehaier Medical Systems Limited. The figures and disclosures below describe Dehaier, not Newegg.
Business context and reporting period
This unaudited 10-Q covers the quarter and nine months ended September 30, 2012, compared with the same periods in 2011. Dehaier develops and distributes medical devices in China, including proprietary products and equipment from international manufacturers; its reporting group includes a Chinese variable interest entity (VIE).
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue, 2012 vs. 2011 | $5.53m vs. $5.69m; down 2.8% | $15.83m vs. $16.35m; down 3.2% |
| Gross profit, 2012 vs. 2011 | $2.07m vs. $2.42m | $6.05m vs. $6.26m |
| Gross margin, 2012 vs. 2011 | 37.4% vs. 42.5% | 38.2% vs. 38.3% |
| Operating income, 2012 vs. 2011 | $1.41m vs. $1.66m | $3.79m vs. $3.88m |
| Net income attributable to Dehaier, 2012 vs. 2011 | $1.04m vs. $1.38m | $2.85m vs. $3.32m |
| Basic earnings per share, 2012 vs. 2011 | $0.23 vs. $0.31 | $0.62 vs. $0.74 |
For the first nine months, operating cash flow was $1.39m, compared with $4.05m used in the prior-year period. Investing cash outflow was $2.72m, mainly for software copyrights; financing provided $0.79m net. Cash declined by $0.53m from year-end 2011 to $3.17m at September 30, 2012.
Working capital was reported at $28.03m. Current assets were $31.96m and current liabilities $3.94m. Short-term borrowings were $2.39m, up from $1.59m at year-end 2011; the loans were secured by a VIE-owned building and/or guaranteed by a company officer. Total liabilities were $4.32m.
Material changes and management commentary
- Medical-device revenue rose to $13.38m for the nine months, from $12.86m. Respiratory and oxygen homecare revenue fell to $2.44m from $3.49m. In Q3, medical-device revenue increased, while homecare revenue declined.
- Management attributed weaker overall sales to lower traditional-device sales as the company shifted toward government procurement and homecare. It said these initiatives were at an early stage.
- Nine-month net income fell 14.5%, partly because the warrant liability generated a non-cash $187,823 charge in 2012 versus a $177,358 gain in 2011. Excluding those warrant fair-value effects, management reported nine-month net income of $3.04m, down 3.7% from $3.16m.
- Q3 gross margin declined to 37.4% from 42.5%, which management attributed to higher raw-material costs and software amortization. It expected these cost pressures to persist in the near term.
- Operating expenses decreased overall. Management expects G&A and selling costs to rise as it invests in R&D, distribution, marketing and homecare services.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance was provided. Management said it believed available working capital would support operations for at least 12 months, while noting that acquisitions or expansion could require operating cash, debt or equity financing.
- Business developments included a three-year Ukraine procurement agreement, an exclusive two-year China distribution agreement for GCE’s EASE II product, and procurement agreements with Beijing hospitals and a medicines company. In October, Dehaier also won a Xinjiang government contract and received a reported RMB118,100 subsidy for short-term loan interest.
- Management was evaluating resource allocation for its Beijing home oxygen therapy service; it said 2012 efforts focused on building the delivery network rather than generating significant revenue.
- Risks evident in the filing include customer and product concentration, collection risk, dependence on Chinese healthcare policies and procurement, cost inflation, and execution of newer homecare and government-project strategies. One customer represented 19% of Q3 revenue; the two leading products represented 75% of Q3 revenue. Accounts receivable, net of allowance, were $13.15m.
- The filing describes potential tax exposure: certain VAT returns for customers had been delayed, with potential liabilities accrued. Dehaier also relied on a preferential 15% PRC income-tax rate; renewal approval was received in October, but the certificate had not yet been received by the filing date. A possible estimated $295,000 severance obligation was not recorded because management considered payment unlikely.
- The company reported no legal proceedings, defaults on senior securities, or material changes in internal control. It concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Dehaier’s, despite the request naming Newegg Commerce.
- Review the complete financial statements and notes, particularly receivable aging and allowance adequacy, contract deposits, and cash conversion.
- Assess whether government procurement and homecare growth can offset declining homecare product sales and support margins.
- Verify the tax-preference certificate, VAT matters, and the terms and collateral/guarantees for short-term borrowings.
- Evaluate the effect of warrant-liability remeasurement and potential dilution from outstanding warrants and stock options.